抗增殖剂减弱了在小鼠和人类实验对象的血栓后静脉壁重塑
Hongji Pu1, Jiahao Lei1, Guodong Du1
1Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Journal of thrombosis and haemostasis : JTH
|October 2, 2024
概括
预防血栓后综合征 (PTS) 是非常重要的,因为它影响了许多深静脉血栓症患者. 抑制细胞增殖是静脉壁重塑的关键因素,在减少PTS症状方面显示出有前途.
科学领域:
- 血管生物学 血管生物学
- 再生医学是一种再生医学.
背景情况:
- 后血症综合征 (PTS) 影响高达50%的深静脉血栓症患者,尽管治疗.
- 目前,没有针对PTS的特殊治疗方法,这凸显了预防的重要性.
研究的目的:
- 为了表征静脉壁重塑后的血栓.
- 在小鼠和人类实验中研究一种抗增殖剂在缓解血栓后静脉壁重塑中的有效性.
主要方法:
- 用图像和组织学评估了静脉壁改造在小鼠和人类受试者身上.
- 在小鼠模型中使用了带有paclitaxel的水凝来评估抗增殖作用.
- 一项试点研究在重症PTS患者中使用了帕克利塔塞尔涂层气球血管造形术,对照组通过倾向评分进行匹配.
主要成果:
- 组织学检查显示,阿尔法平滑肌细胞和纤维细胞特异蛋白1阳性细胞的显著增殖.
- 在小鼠模型中,帕克利塔克塞尔治疗有效地抑制了静脉壁的重塑.
- 与对照组相比,用药物涂层气球治疗的患者的临床得分 (Villalta和静脉临床严重程度) 改善,除了血栓复发之外,没有重大不良事件.
结论:
- 细胞增殖是血栓后静脉壁重塑的一个关键驱动因素.
- 抑制细胞增殖有效地减少了临床前模型中的重塑,并可能缓解严重PTS患者的症状.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
01:30Venous Thrombosis I: Introduction
3
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
3